Table 1. Clinical characteristics of patients.
| Characteristics | Prostatectomy discovery cohort (n = 63) | ||
|---|---|---|---|
| BCR (n = 21) | Non-BCR (n = 42) | p value | |
| Time from RP to BCR1 (median), months | 19.4 (2.5–98.6) | ||
| Time from RP to last PSA follow-up, months | 97.4 (58.1–166.8) | ||
| Range of surgery year | 1998–2008 | 1997–2007 | |
| Age | |||
| Median (IQR) | 58.3 (45–70) | 56.4 (40–75) | 0.26 |
| < 50 | 3 (14%) | 11 (26%) | |
| 50–60 | 10 (48%) | 17 (41%) | |
| 60–70 | 7 (33%) | 11 (26%) | |
| > 70 | 1 (5%) | 3 (7%) | |
| Race | |||
| American Caucasian | 14 (67%) | 27 (64%) | |
| American African | 6 (28%) | 13 (31%) | |
| Hispanic/Other | 1 (5%) | 2 (5%) | |
| Clinical tumor stage | |||
| T1 | 12 (57%) | 24 (57%) | |
| T2 | 7 (33%) | 17 (40%) | |
| Unknown | 2 (10%) | 1 (3%) | |
| Pre-surgery PSA | |||
| Median (IQR) | 4.7 (1.8–13.6) | 4.7 (0.7–14.2) | 0.74 |
| BMI | |||
| Median (IQR) | 27 (19–34) | 26 (16–33) | 0.11 |
| Prostate weight | |||
| Median (IQR) | 39.5 (23.4–48.4) | 36.6 (22.3–63.7) | 0.46 |
| Signs of further progression | |||
| positive margins | Negative | Negative | |
| Extra-capsular extension | Negative | Negative | |
| Seminal vesicle invasion | Negative | Negative | |
| Pathology GS | |||
| ≤ 6 (3+3) | 12 (57%) | 30 (71%) | |
| 7 (3+4) | 9 (43%) | 12 (29%) | |
| Pathology tumor stage | |||
| T2 | 21 (100%) | 40 (95%) | |
| T3A | 0 (0%) | 2 (5%) | |
BCR = Biochemical recurrence, RP = Radical prostatectomy, IQR = interquartile range, PSA = Prostate-specific antigen, GS = Gleason score.